Yutian Wu

Yutian Wu

Auto-generated profile, based on publicly available information

Yutian Wu

State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), and Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 April 2024 in ACS Sustainable Chemistry & Engineering
Verified
Journal Article
Closed access
YWYutian Wu
Yutian Wu
PLPengju Li
Pengju Li
LCLong Chen
Long Chen
ALAo Li
Ao Li
CLChunyang Li
Chunyang Li
MSMatthew V. Sheridan
Matthew V. Sheridan

7 January 2009 in Instrumentation Science & Technology
Verified
Journal Article
Closed access
YWYiwen Wu
Yiwen Wu
JWJun Wen
Jun Wen
GFGuorong Fan
Guorong Fan
YWYutian Wu
Yutian Wu
To investigate the pharmacokinetic characteristics of a novel nanoliposome-entrapped docetaxel injection, an anti-tumor agent, a high-throughput analytical method based on liquid chromatography with positive ion electrospray ionization (ESI) coupled to tandem mass spectrometry detection (LC-MS/MS) was developed for the determination of docetaxel in beagle dog plasma using paclitaxel as the internal standard (I.S.). Most liquid transfer steps, including preparation of calibration standards and quality control samples, as well as the addition of the I.S., were performed by using eight-channel pipetting tools. The analyte and internal standard were isolated from 50 µL plasma samples and chromatographed on a Ultimate XB C-8 column (50 mm × 4.6 mm, 5 µm) with a mobile phase consisting of methanol–water–formic acid (90:10:0.01, v/v/v)pumped at 0.3 mL/min. The method had a chromatographic total run time of 3 min. A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 830.0 → 549.0 (docetaxel) and 876.0 → 591.0 (paclitaxel) used for quantitation. The method was sensitive, with a lower limit of quantitation (LLOQ) of 1 ng/mL and good linearity in the range 1–500 ng/mL for docetaxel. All the validation data, such as accuracy, precision, and inter-day repeatability, were within the required limits. The method was successfully applied to initial pharmacokinetic study of nanoliposome-entrapped docetaxel injection in beagle dogs, and the statistical results of the pharmacokinetic data clearly suggest the novel formulation vehicle does control docetaxel's acute side effects to some extent.